Selumetinib is a MEK1/2 inhibitor for cancer research
**Background** The Ras/MAPK (mitogen-activated protein kinase) signaling pathway plays a critical role in regulating cell proliferation, differentiation, and survival. Dysregulation of this pathway, often through mutations in Ras or B-Raf,…